Belova59/PixabayA US study of 6451 people with HIV who switched from antiretroviral drug regimens containing the older form of tenofovir, tenofovir disoproxil fumarate (TDF), to regimens containing the newer form, tenofovir alafenamide (TAF), shows rises in participants’ cholesterol and triglycerides – blood lipids (fats) that raise the risk of cardiovascular disease.
The risk was moderated by the fact that levels of high-density lipoprotein (HDL, also known as ‘good’ cholesterol), which protects against heart disease, also increased. Nonetheless, there was a slight but significant rise in the ten-year risk of cardiovascular disease in patients switching from TDF to TAF.
Read the full story at Aidsmap.
Source : Aidsmap
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.